Corporate Headquarters
505 Lomas Santa Fe Drive
Suite 270
Solana Beach, CA 92075

(858)345-1494 Tel.

Investor Relations :: Overview

Stock price graph

Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. EVK-001 is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration.


May 11, 2016 at 4:30 PM ET
Evoke Pharma First Quarter 2016 Conference Call

Mar 10, 2016 at 4:30 PM ET
Evoke Pharma Fourth Quarter 2015 Conference Call

Nov 12, 2015 at 4:30 PM ET
Evoke Pharma Third Quarter 2015 Conference Call

Presentations and Posters

Evoke Pharma Presentation at DDW Conference May 23, 2016 PDF 972.7 KB  
Evoke Pharma Investor Presentation PDF 1.6 MB  
Evoke Pharma Presentation at the LD Micro Conference. December 4, 2014 PDF 1.8 MB  

Recent Releases

Jun 1, 2016
Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis

May 24, 2016
Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016

View all releases »